Cancers (Jun 2022)
Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol
- Monica Messina,
- Alfonso Piciocchi,
- Tiziana Ottone,
- Stefania Paolini,
- Cristina Papayannidis,
- Federica Lessi,
- Nicola Stefano Fracchiolla,
- Fabio Forghieri,
- Anna Candoni,
- Andrea Mengarelli,
- Maria Paola Martelli,
- Adriano Venditti,
- Angelo Michele Carella,
- Francesco Albano,
- Valentina Mancini,
- Bernardi Massimo,
- Valentina Arena,
- Valeria Sargentini,
- Mariarita Sciumè,
- Domenico Pastore,
- Elisabetta Todisco,
- Giovanni Roti,
- Sergio Siragusa,
- Marco Ladetto,
- Stefano Pravato,
- Eleonora De Bellis,
- Giorgia Simonetti,
- Giovanni Marconi,
- Claudio Cerchione,
- Paola Fazi,
- Marco Vignetti,
- Sergio Amadori,
- Giovanni Martinelli,
- Maria Teresa Voso
Affiliations
- Monica Messina
- GIMEMA Foundation, 00182 Roma, Italy
- Alfonso Piciocchi
- GIMEMA Foundation, 00182 Roma, Italy
- Tiziana Ottone
- Ematologia, Dipartimento di Biomedicina e Prevenzione, Università di Roma Tor Vergata, 00133 Roma, Italy
- Stefania Paolini
- IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli” Bologna, 40138 Bologna, Italy
- Cristina Papayannidis
- IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli” Bologna, 40138 Bologna, Italy
- Federica Lessi
- Ematologia ed Immunologia Clinica, Università degli Studi di Padova, 1222 Padua, Italy
- Nicola Stefano Fracchiolla
- UOC Ematologia, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milano, Italy
- Fabio Forghieri
- UO Ematologia-AOU Policlinico di Modena, 41125 Modena, Italy
- Anna Candoni
- Clinica Ematologica, ASUFC, Università degli Studi di Udine, 33100 Udine, Italy
- Andrea Mengarelli
- UO Ematologia-IRCCS Istituto Nazionale Tumori Tumori Regina Elena, 00128 Roma, Italy
- Maria Paola Martelli
- Sezione di Ematologia ed Immunologia Clinica, Università degli Studi di Perugia, 06123 Perugia, Italy
- Adriano Venditti
- Ematologia, Dipartimento di Biomedicina e Prevenzione, Università di Roma Tor Vergata, 00133 Roma, Italy
- Angelo Michele Carella
- Ematologia e Centro Trapianti CSE Fondazione IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, Italy
- Francesco Albano
- Hematology and Stem Cell Transplantation Unit, Department of Emergency and Organ Transplantation (D.E.T.O.), University of Bari Aldo Moro, 70121 Bari, Italy
- Valentina Mancini
- Ospedale Niguarda Ca Granda-SC Ematologia Blocco SUD, 20162 Milano, Italy
- Bernardi Massimo
- IRCCS San Raffaele Scientific Institute, 20132 Milano, Italy
- Valentina Arena
- GIMEMA Foundation, 00182 Roma, Italy
- Valeria Sargentini
- GIMEMA Foundation, 00182 Roma, Italy
- Mariarita Sciumè
- UOC Ematologia, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milano, Italy
- Domenico Pastore
- UOC Ematologia Brindisi, 72100 Brindisi, Italy
- Elisabetta Todisco
- Onco-Hematology Division, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy
- Giovanni Roti
- Azienda Ospedaliera Universitaria di Parma, Ematologia, Università di Parma, 43126 Parma, Italy
- Sergio Siragusa
- U.O. di Ematologia con Trapianto-A.U. Policlinico Paolo Giaccone, 90127 Palermo, Italy
- Marco Ladetto
- AO SS Antonio e Biagio Arrigo, 15121 Alessandria, Italy
- Stefano Pravato
- Ematologia ed Immunologia Clinica, Università degli Studi di Padova, 1222 Padua, Italy
- Eleonora De Bellis
- Hematology Unit, Azienda Sanitaria Universitaria Giuliano Isontina, 34148 Trieste, Italy
- Giorgia Simonetti
- Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, 47014 Meldola, Italy
- Giovanni Marconi
- Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori [M1] (IRST) IRCCS, 47014 Meldola, Italy
- Claudio Cerchione
- Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori [M1] (IRST) IRCCS, 47014 Meldola, Italy
- Paola Fazi
- GIMEMA Foundation, 00182 Roma, Italy
- Marco Vignetti
- GIMEMA Foundation, 00182 Roma, Italy
- Sergio Amadori
- Ematologia, Dipartimento di Biomedicina e Prevenzione, Università di Roma Tor Vergata, 00133 Roma, Italy
- Giovanni Martinelli
- Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, 47014 Meldola, Italy
- Maria Teresa Voso
- Ematologia, Dipartimento di Biomedicina e Prevenzione, Università di Roma Tor Vergata, 00133 Roma, Italy
- DOI
- https://doi.org/10.3390/cancers14123012
- Journal volume & issue
-
Vol. 14,
no. 12
p. 3012
Abstract
IDH1/2 mutations are common in acute myeloid leukemia (AML) and represent a therapeutic target. The GIMEMA AML1516 observational protocol was designed to study the prevalence of IDH1/2 mutations and associations with clinico-biological parameters in a cohort of Italian AML patients. We analyzed a cohort of 284 AML consecutive patients at diagnosis, 139 females and 145 males, of a median age of 65 years (range: 19–86). Of these, 38 (14%) harbored IDH1 and 51 (18%) IDH2 mutations. IDH1/2 mutations were significantly associated with WHO PS >2 (p p = 0.021) when compared to IDH1/2-WT. Furthermore, patients with IDH1 mutations were more frequently NPM1-mutated (p = 0.007) and had a higher platelet count (p = 0.036). At relapse, IDH1/2 mutations were detected in 6 (25%) patients. As per the outcome, 60.5% of IDH1/2-mutated patients achieved complete remission; overall survival and event-free survival at 2 years were 44.5% and 36.1%, respectively: these rates were similar to IDH1/2-WT. In IDH1/2-mutated patients, high WBC proved to be an independent prognostic factor for survival. In conclusion, the GIMEMA AML1516 confirms that IDH1/2 mutations are frequently detected at diagnosis and underlines the importance of recognizing IDH1/2-mutated cases up-front to offer the most appropriate therapeutic strategy, given the availability of IDH1/2 inhibitors.
Keywords
